Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer (CHEMOFIRE-2)

NCT04093141 is registered in ClinicalTrials.gov with Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery as lead sponsor.

NCT NCT04093141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04093141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer (CHEMOFIRE-2)
Lead sponsor
Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Phase
Not applicable
Overall status
Unknown status
Start date
May 1, 2019
Completion date
May 31, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable pancreatic cancer